Skip to content
BioSupply Trends Quarterly logo
  • About Us
  • About Us
Subscribe
  • News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
BioSupply Trends Quarterly logo

Category: Research and Development

$13M NIH Grant Funds Research to Rejuvenate Immune System in Older Adults

image of older women

University of Arizona Health Sciences researchers have received a $13.1 million grant from the National Institute on Aging to continue studies aimed at rejuvenating the immune system of older people to improve health throughout the lifespan.

FcRn Antagonists: A Panoply of Autoimmune Disorders Now in the Development Pipeline

FcRn Antagonists

Specifically designed to blockade the physiologic IgG recycling function of endothelial cell neonatal crystallizable fragment receptor (FcRn), FcRn antagonists represent a new class of monoclonal antibody-based drugs that have been shown to mediate a sharp, dose-dependent reduction in circulation IgG levels.

Message for At-Risk Adults: Flu Vaccination Will Reduce Your Risk of Cardiovascular Disease and Death

Woman receiving a flu vaccine

With influenza apparently returning with a vengeance this season, the Centers for Disease Control and Prevention is once again alerting the public that vaccination is the most effective way to prevent infection from and to minimize risk of severe symptoms and hospitalization for serious flu-related complications.

High-Dose IVIG Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments

Photo of foot exam

Italian investigators conducted a trial to assess the safety and efficacy of IVIG in treatment-resistant painful diabetic polyneuropathy (DPN).

COVID-19 Infection Alters Pregnant Mothers’ and Their Newborns’ Immunity

Mother kissing baby's head

Investigators found COVID-19 infection altered the mothers’ immunity at delivery, and gestational COVID-19 exposure alters the immunity of newborns.

Study Shows COVID-19 Infection Correlates with Autoimmune Markers

Illustration of viruses

A new study demonstrates how severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) infection could be associated with an autoimmune response and development of autoantibodies.

Transition from Clinic- to Home-Based IVIG/SCIG Is Successful to Decrease Exposure to COVID-19

Photo of ivig patient

Transition of clinic-based to home-based intravenous immune globulin (IVIG)/subcutaneous IG (SCIG) infusion can be successfully done to decrease potential exposure during a pandemic in a high-risk immunosuppressed population.

IVIG Plus Glucocorticoids Effective for Treating COVID-19 Pediatric Syndrome

Photo of healthcare worker listening to pediatric patient's chest

A large multicenter clinical trial has found intravenous immune globulin (IVIG) plus glucocorticoids may be better than IVIG alone for treating multisystem inflammatory syndrome in children (MIS-C) caused by COVID-19.

Studies Reveal Antibody Responses of Pregnant Women Infected with SARS-CoV-2

Picture of a pregnant woman

Two recent studies effectively determined the antibody responses of pregnant women infected with SARS-CoV-2 and the effect of the fetal sex on those responses, as well as the direct clinical implications for COVID-19 infection and future maternal-fetal vaccination strategies.

Gene Therapy for Hemoglobinopathies

dna illustration

New clinical studies show gene therapy may offer a cure for these chronic and expensive diseases in five to 10 years.

← Previous
Next →
BioSupply Trends Quarterly logo
FFF Enterprises logo
  • Current Issue
  • Past Issues
  • Resources
  • Current Issue
  • Past Issues
  • Resources
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
Facebook-f Instagram Linkedin-in Youtube

FFF Enterprises.com | Privacy Statement | Terms of Use | California Consumer Privacy Act (CCPA) Opt-Out Icon

FFF Enterprises.com
Privacy Statement
Terms of Use
California Consumer Privacy Act (CCPA) Opt-Out Icon

©2024 FFF Enterprises, Inc. All Rights Reserved. Property of FFF Enterprises, Inc.

The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.